Clinical Trial Update: HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating HRS9531 injections in obese adults with heart failure with preserved ejection fraction; the study is currently active but not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• HRS9531

Snippet

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Conditions: Heart Failure With Preserved Ejection Fraction | Phase 2 | Status: ACTIVE_NOT_RECRUITING